Trial reportPsychotherapy and psychosomatics2019
Improving Pleasure and Motivation in Schizophrenia: A Randomized Controlled Clinical Trial.
Trial report in Psychotherapy and psychosomatics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02593058 (Positive Emotions Program for Schizophrenia), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Positive Emotions Program for Schizophrenia (PEPS): A Randomized Controlled Study on Improving Pleasure and Motivation in Schizophrenia
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Strategies for Psychiatric Rehabilitation and their Cognitive Outcomes in Schizophrenia: Review of Last Five-year Studies.Clinical practice and epidemiology in mental health : CP & EMH · 2021Pooled it
- A Digital Therapeutic Intervention for Negative Symptoms of Schizophrenia: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial.JMIR research protocols · 2025Article
- Left amygdala alterations mediate the effects of negative symptoms on social dysfunction in schizophrenia.Schizophrenia (Heidelberg, Germany) · 2025Article
- Motivation and Pleasure Deficits Undermine the Benefits of Social Affiliation in Psychosis.Clinical psychological science : a journal of the Association for Psychological Science · 2024Article
- Cognitive Impairments in Drug-Naive Patients With First-Episode Negative Symptom-Dominant Psychosis.JAMA network open · 2024Article
- Efficacy and feasibility of aerobic exercise interventions as an adjunctive treatment for patients with schizophrenia: a meta-Analysis.Schizophrenia (Heidelberg, Germany) · 2024Article
- Towards a Non-pharmacological Intervention on Apathy in Korsakoff's Syndrome: A Systematic Narrative Review Across Different Clinical Conditions.Neuropsychiatric disease and treatment · 2024Review
- Experiences of schizophrenia patients with treatment buddy support during the COVID-19 pandemic.Health SA = SA Gesondheid · 2024Article
- Attitude towards mental help-seeking, motivation, and economic resources in connection with positive, negative, and general psychopathological symptoms of schizophrenia: a pilot study of a psychoeducation program.Frontiers in psychiatry · 2024Article
- Efficacy of a Smartphone App in Enhancing Medication Adherence and Accuracy in Individuals With Schizophrenia During the COVID-19 Pandemic: Randomized Controlled Trial.JMIR mental health · 2023Article
- Deficits in Key Brain Network for Social Interaction in Individuals with Schizophrenia.Brain sciences · 2023Article
- Turning the Spotlight on Apathy: Identification and Treatment in Schizophrenia Spectrum Disorders.Schizophrenia bulletin · 2023Article
- Markov chain analysis indicates that positive and negative emotions have abnormal temporal interactions during daily life in schizophrenia.Journal of psychiatric research · 2023Article
- "Goals in Focus"-a targeted CBT approach for motivational negative symptoms of psychosis: study protocol for a randomized-controlled feasibility trial.Pilot and feasibility studies · 2023Article
- Negative symptoms in first episode schizophrenia: treatment response across the 2-year follow-up of the "Parma Early Psychosis" program.European archives of psychiatry and clinical neuroscience · 2022Article
- An Evaluation of an Online Training Platform for Teaching Positive Emotions for People With Schizophrenia.Frontiers in psychiatry · 2022Article
- Splitting Things Apart to Put Them Back Together Again: A Targeted Review and Analysis of Psychological Therapy RCTs Addressing Recovery From Negative Symptoms.Frontiers in psychiatry · 2022Review
- Validation of the Korean Version of the Anticipatory and Consummatory Interpersonal Pleasure Scale in Non-help-seeking Individuals.Frontiers in psychology · 2022Article
- EPA guidance on treatment of negative symptoms in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNegative symptoms are frequent in patients with schizophrenia and are associated with marked impairments in social functioning. The efficacy of drug-based treatments and psychological interventions on primary negative symptoms remains limited. The Positive Emotions Programme for Schizophrenia (PEPS) is designed to improve pleasure and motivation in schizophrenia patients by targeting emotion regulation and cognitive skills relevant to apathy and anhedonia. The main hypothesis of this study is that patients who attend 8 one-hour sessions of PEPS and treatment as usual (TAU) will have lower total apathy-avolition and anhedonia-asociality composite scores on the Scale for the Assessment of Negative Symptoms (SANS) than patients who attend only TAU.
methodsEighty participants diagnosed with schizophrenia or schizoaffective disorder were randomized to receive either TAU or PEPS + TAU. The participants were assessed by independent evaluators before randomization (T0), in a post-test after 8 weeks of treatment (T1) and at a 6-month follow-up (T2).
resultsThe post-test results and 6-month follow-up assessments according to an intention-to-treat analysis showed that the apathy and anhedonia composite scores on the SANS indicated statistically greater clinical improvements in PEPS participants than in non-PEPS participants. In the post-test, anhedonia but not apathy was significantly improved, thus favouring the PEPS condition. These results were sustained at the 6-month follow-up.
conclusionsPEPS is an effective intervention to reduce anhedonia in schizophrenia. PEPS is a short, easy-to-use, group-based, freely available intervention that is easy to implement in a variety of environments (ClinicalTrials.gov ID: NCT02593058).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.